Newsfeeds Archive - Spark Newswire

2 minute read

Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting

April 8, 8:34 AM

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance

CHRS

4 minute read

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

January 22, 2:08 PM

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.

ACRS

1 minute read

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

By Vandana Singh

January 22, 10:41 AM

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

CHRS

3 minute read

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

January 22, 9:21 AM

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

ACRS

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

January 19, 9:06 AM

Gainers Mesoblast (NASDAQ:MESO) shares increased by 22.1% to $2.1 during Friday’s pre-market session. The company’s market cap stands…

ADIL

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

January 18, 5:31 PM

Gainers Assure Hldgs (NASDAQ:IONM) stock moved upwards by 13.3% to $0.31 during Thursday’s after-market session. The company’s market…

AIMD

4 minute read

Coherus Presents Phase 2 Clinical Data On Casdozokitug, A First-in-Class IL-27-Targeted Antibody, At The 2024 ASCO GI Cancers Symposium; The Primary Endpoint Of The Lead-in Portion Of The Study Was Safety And Tolerability

By Benzinga Newsdesk

January 18, 5:16 PM

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –– Data support casdozo as a promising novel immuno-oncology agent with

CHRS

2 minute read

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday

By Avi Kapoor

January 10, 11:27 AM

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.

AEHR

3 minute read

Coherus Announces U.S. Launch Of LOQTORZI; Offers First And Only FDA-Approved Treatment For NPC In All Lines Of Therapy

By Benzinga Newsdesk

January 2, 9:31 AM

– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with

CHRS

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet

By Chris Katje

December 29, 12:04 PM

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

BMY